Antonio Emanuele Elia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5228113/publications.pdf

Version: 2024-02-01

53 papers	2,683 citations	218592 26 h-index	189801 50 g-index
59 all docs	59 docs citations	59 times ranked	4425 citing authors

#	Article	IF	Citations
1	PINK1 mutations are associated with sporadic early-onset parkinsonism. Annals of Neurology, 2004, 56, 336-341.	2.8	447
2	EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology, 2011, 18, 5-18.	1.7	350
3	Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2016, 23, 45-52.	1.7	175
4	Effects of <scp>COVID</scp>â€19 on Parkinson's Disease Clinical Features: A <scp>Communityâ€Based Caseâ€Control</scp> Study. Movement Disorders, 2020, 35, 1287-1292.	2.2	148
5	Efficient RT-QuIC seeding activity for Î±-synuclein in olfactory mucosa samples of patients with Parkinsonâ€™s disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106
6	Botulinum neurotoxins for postâ€stroke spasticity in adults: A systematic review. Movement Disorders, 2009, 24, 801-812.	2.2	98
7	Isolated limb dystonia as presenting feature of Parkin disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 827-828.	0.9	91
8	<scp>GBAâ€Related</scp> Parkinson's Disease: Dissection of Genotypeâ€“Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	2.2	83
9	The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology, 2005, 64, 1958-1960.	1.5	81
10	Skin Î±-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. Scientific Reports, 2018, 8, 14246.	1.6	75
11	PINK1heterozygous rare variants: prevalence, significance and phenotypic spectrum. Human Mutation, 2008, 29, 565-565.	1.1	74
12	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Movement Disorders, 2001, 16, 999-1006.	2.2	65
13	Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 134-137.	1.1	63
14	In vivo evidence for GABA_A receptor changes in the sensorimotor system in primary dystonia. Movement Disorders, 2011, 26, 852-857.	2.2	61
15	Substantia nigra in Parkinsonâ€™s disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurological Sciences, 2014, 35, 753-758.	0.9	50
16	Skin Nerve Phosphorylated Î±-Synuclein Deposits in Parkinson Disease With Orthostatic Hypotension. Journal of Neuropathology and Experimental Neurology, 2018, 77, 942-949.	0.9	40
17	Non-DYT1 early-onset primary torsion dystonia: Comparison with DYT1 phenotype and review of the literature. Movement Disorders, 2006, 21, 1411-1418.	2.2	37
18	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiology of Aging, 2014, 35, 408-417.	1.5	36

#	Article	IF	Citations
19	Punding and computer addiction in Parkinson's disease. Movement Disorders, 2006, 21, 1217-1218.	2.2	35
20	Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology, 2015, 84, 1669-1672.	1.5	35
21	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3588-3597.	1.8	32
22	Concurrent AFG3L2 and SPG7 mutations associated with syndromic parkinsonism and optic atrophy with aberrant OPA1 processing and mitochondrial network fragmentation. Human Mutation, 2018, 39, 2060-2071.	1.1	32
23	<scp>EIF2AK2</scp> Missense Variants Associated with Early Onset Generalized Dystonia. Annals of Neurology, 2021, 89, 485-497.	2.8	32
24	Motor features and response to oral levodopa in patients with Parkinsonâ€™s disease under continuous dopaminergic infusion or deep brain stimulation. European Journal of Neurology, 2012, 19, 76-83.	1.7	31
25	Alphaâ€synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees. Movement Disorders, 2013, 28, 813-817.	2.2	29
26	Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Movement Disorders, 2006, 21, 1232-1235.	2.2	28
27	Telethermographic findings after uncomplicated and septic total knee replacement. Knee, 2012, 19, 193-197.	0.8	28
28	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Molecular Neurodegeneration, 2021, 16, 82.	4.4	28
29	Quantitative gait analysis in parkin disease: Possible role of dystonia. Movement Disorders, 2016, 31, 1720-1728.	2.2	26
30	Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiology of Aging, 2016, 45, 213.e1-213.e2.	1.5	25
31	Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation. Neurogenetics, 2017, 18, 175-178.	0.7	23
32	Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon, 2009, 54, 634-638.	0.8	21
33	Differential diagnosis of dystonia. European Journal of Neurology, 2010, 17, 1-8.	1.7	21
34	Patient Affected by Beta-Propeller Protein-Associated Neurodegeneration: A Therapeutic Attempt with Iron Chelation Therapy. Frontiers in Neurology, 2017, 8, 385.	1.1	18
35	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. Neurological Sciences, 2021, 42, 2637-2644.	0.9	18
36	Onset and progression of primary torsion dystonia in sporadic and familial cases. European Journal of Neurology, 2006, 13, 1083-1088.	1.7	15

#	Article	IF	Citations
37	Short- and long-term motor outcome ofÂSTN-DBS in Parkinsonâ€™s Disease: focus on sex differences. Neurological Sciences, 2022, 43, 1769-1781.	0.9	15
38	Low-Voltage Bilateral Pallidal Stimulation for Severe Meige Syndrome in a Patient With Primary Segmental Dystonia. Operative Neurosurgery, 2010, 67, onsE308.	0.4	14
39	Overall Efficacy and Safety of Safinamide in Parkinsonâ€™s Disease: A Systematic Review and a Meta-analysis. Clinical Drug Investigation, 2021, 41, 321-339.	1.1	14
40	Psychosocial difficulties in patients with Parkinsonâ€™s disease. International Journal of Rehabilitation Research, 2017, 40, 112-118.	0.7	13
41	Dystonia gravidarum: A new case with a long follow-up. Movement Disorders, 2007, 22, 564-566.	2.2	12
42	Clinical and polygraphic study of familial paroxysmal kinesigenic dyskinesia with PRRT2 mutation. Epileptic Disorders, 2013, 15, 123-127.	0.7	11
43	Levodopaâ€“carbidopa intrajejunal infusion in Parkinsonâ€™s disease: untangling the role of age. Journal of Neurology, 2021, 268, 1728-1737.	1.8	9
44	Normal cardiovascular reflex testing in patients withparkin disease. Movement Disorders, 2007, 22, 528-532.	2.2	8
45	Parkinsonism and Nigrostriatal Damage Secondary to <scp>CSF1R</scp>â€Related Primary Microgliopathy. Movement Disorders, 2020, 35, 2360-2362.	2.2	6
46	Sensory trick in task-specific tremor. Neurological Sciences, 2017, 38, 1341-1342.	0.9	5
47	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€“Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	1.7	4
48	Emerging parkinsonian phenotypes. Revue Neurologique, 2010, 166, 834-840.	0.6	3
49	Prevalence of psychiatric disorders in patients with inherited or idiopathic dystonia. Parkinsonism and Related Disorders, 2018, 47, 84-85.	1.1	3
50	Amyotrophic onset in GCH1 dopa-responsive dystonia. Current Journal of Neurology, 0, , .	0.0	1
51	Response to letter by Dr Neil Murray. European Journal of Neurology, 2011, 18, e62-e62.	1.7	0
52	Reply to Dr MichaudetÂal.. European Journal of Neurology, 2015, 22, e78-e78.	1.7	0
53	Cerebrospinal fluid neuropathological biomarkers in beta-propeller protein-associated neurodegeneration, with complicated parkinsonian phenotype. Parkinsonism and Related Disorders, 2022, 98, 38-40.	1.1	0